# GLP-1s and fatty liver: what the trials measured · PepVault

Source: https://pepvault.app/guides/glp-1-and-fatty-liver

Last updated: 2026-11-20

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

[Guides](https://pepvault.app/guides) [GLP-1s](https://pepvault.app/guides#glp1)

# GLP-1s and fatty liver: what the trials measured

Reviewed November 2026 21 sources [Published by PepVault](https://pepvault.app/guides/how-we-research)

Wegovy is approved for MASH, the inflamed fatty liver. What semaglutide, tirzepatide, survodutide and retatrutide did to liver fat and scarring, side by side.

- **Last reviewed:** Nov 20, 2026
- **Sources:** 21
- **Questions:** 7
- **Compounds:** 6

## The short answer

One GLP-1 is approved for fatty liver. Since August 15, 2025, Wegovy (semaglutide 2.4 mg) has FDA accelerated approval for MASH, the inflamed form, in adults with moderate to advanced scarring and no cirrhosis. In its trial, MASH cleared in 63% of people against 34% on placebo at 72 weeks. Tirzepatide, survodutide and retatrutide cut liver fat sharply in trials but are not approved for it.

- Wegovy (semaglutide 2.4 mg) is the one GLP-1 approved for MASH, since August 15, 2025, for scarring at stage F2 or F3 without cirrhosis.
- In biopsy trials, MASH cleared in 63% on semaglutide and up to 62% on tirzepatide, against 34% and 10% on placebo.
- Retatrutide cut liver fat by up to 82% in 24 weeks; survodutide cut it by 30% or more in 84% of people.
- No drug has yet shown fewer cirrhosis cases or liver deaths; those trials are still running.

Every number checked at its primary source · Nov 20, 2026 · [21 sources](https://pepvault.app/guides/glp-1-and-fatty-liver#sources) · [How we research](https://pepvault.app/guides/how-we-research)

**Evidence:** Phase 3 biopsy trial for semaglutide (the basis of Wegovy's accelerated approval); phase 2 biopsy trials for tirzepatide, survodutide and efinopegdutide; MRI-only trials for retatrutide and survodutide's phase 3; no drug yet shown to prevent cirrhosis or liver deaths.

## Is any GLP-1 approved for fatty liver?

One, as of November 2026. On August 15, 2025 the FDA approved Wegovy injection for noncirrhotic MASH with moderate to advanced liver fibrosis (scarring at stage F2 or F3) in adults[2](https://pepvault.app/guides/glp-1-and-fatty-liver#source-2). It is an **accelerated approval**: the FDA accepted improvements seen in liver biopsies as a sign likely to predict real benefit, and Novo Nordisk must finish a 240-week trial that counts what matters most, progression to cirrhosis, liver failure events, transplants and deaths[2](https://pepvault.app/guides/glp-1-and-fatty-liver#source-2). The current label, published June 2026, keeps the indication with that condition attached[1](https://pepvault.app/guides/glp-1-and-fatty-liver#source-1). The UK's medicines regulator followed on July 3, 2026 with a conditional approval for the same group[17](https://pepvault.app/guides/glp-1-and-fatty-liver#source-17).

The approval belongs to Wegovy alone. Wegovy tablets carry no MASH use on the same label[1](https://pepvault.app/guides/glp-1-and-fatty-liver#source-1). Ozempic is the same molecule, but its label carries none, and neither do Zepbound or Mounjaro (tirzepatide), whose labels were revised in August 2026[19](https://pepvault.app/guides/glp-1-and-fatty-liver#source-19) [20](https://pepvault.app/guides/glp-1-and-fatty-liver#source-20) [21](https://pepvault.app/guides/glp-1-and-fatty-liver#source-21). The first drug of any kind approved for MASH was not a GLP-1: Rezdiffra (resmetirom), a daily pill, on March 14, 2024[10](https://pepvault.app/guides/glp-1-and-fatty-liver#source-10).

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

PepVault logs your weekly shot and keeps your weigh-ins on one chart, and its Bloodwork page stores liver results such as ALT, AST and GGT by date, so the numbers your doctor follows sit in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-flow&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## What do MASLD, MASH and NAFLD mean?

They are the old and new names for the same diseases. In 2023, 236 liver specialists and patient advocates from 56 countries voted to drop "nonalcoholic fatty liver disease" (NAFLD), a name defined by what it was not and one most panelists found stigmatizing[12](https://pepvault.app/guides/glp-1-and-fatty-liver#source-12). Fat building up in the liver is now **MASLD**, metabolic dysfunction-associated steatotic liver disease, and it needs at least one of five heart-and-metabolism risk factors such as excess weight or waist size, or high blood pressure[12](https://pepvault.app/guides/glp-1-and-fatty-liver#source-12). Its inflamed, damaging form, once NASH, is now MASH: metabolic dysfunction-associated steatohepatitis. People with MASLD who also drink more than a set weekly amount fall into a new middle group, MetALD[12](https://pepvault.app/guides/glp-1-and-fatty-liver#source-12).

Scarring is graded from F0 (none) to F4 (cirrhosis)[9](https://pepvault.app/guides/glp-1-and-fatty-liver#source-9). A healthy liver holds under 5% fat[5](https://pepvault.app/guides/glp-1-and-fatty-liver#source-5). Papers before 2023 say NAFLD and NASH; the trials below are the same diseases under either name. PepVault's glossary explains MASH at pepvault.app/glossary/mash, and pepvault.app/conditions/fatty-liver-disease gathers the liver studies we cover.

## What did each drug do to liver fat and scarring?

Two kinds of result appear in these trials. A scan called **MRI-PDFF** measures the share of the liver that is fat. A **biopsy**, a thin needle sample of liver read under a microscope, shows whether the inflammation cleared ("MASH resolved") and whether the scarring fell by at least one stage. The table gives each drug's result against its own placebo group. Every row is a separate trial, in different people over different lengths of time, so read each drug against its placebo, not against the row above.

| Drug, trial | Who and how long | Liver fat on MRI | MASH resolved, scarring not worse | Scarring down 1+ stage |
| --- | --- | --- | --- | --- |
| Semaglutide 2.4 mg weekly, ESSENCE (phase 3) | 800 with MASH, F2–F3; 72 weeks | Not a main result | 62.9% vs 34.3% | 36.8% vs 22.4% |
| Tirzepatide 5, 10, 15 mg weekly, SYNERGY-NASH (phase 2) | 190 with MASH, F2–F3; 52 weeks | Not a main result | 44%, 56%, 62% vs 10% | 55%, 51%, 51% vs 30% |
| Tirzepatide 10 and 15 mg, SURPASS-3 MRI (phase 3 substudy) | 296 with type 2 diabetes and likely fatty liver; 52 weeks | −8.1 points vs −3.4 on insulin (from 15.7%) | No biopsy | No biopsy |
| Survodutide 2.4, 4.8, 6.0 mg weekly (phase 2) | 293 with MASH, F1–F3; 48 weeks | 30%+ drop in 63%, 67%, 57% vs 14% | MASH improved (not resolved): 47%, 62%, 43% vs 14% | 34%, 36%, 34% vs 22% |
| Survodutide 6.0 mg weekly, SYNCHRONIZE-MASLD (phase 3) | 216 with obesity and at-risk MASLD; 48 weeks | 30%+ drop in 84.2% vs 24.3% | No biopsy endpoint | No biopsy endpoint |
| Retatrutide 1, 4, 8, 12 mg weekly (phase 2 substudy) | 98 with MASLD and 10%+ liver fat; 24 weeks | −42.9%, −57.0%, −81.4%, −82.4% vs +0.3% | No biopsy | No biopsy |
| Efinopegdutide 4, 7, 10 mg weekly (phase 2b) | 381 with MASH, F2–F3; 52 weeks | Not a main result | 56%, 63%, 61% vs 13% | 43%, 52%, 34% vs 21% |
| Resmetirom 80 or 100 mg daily pill, MAESTRO-NASH (phase 3; not a GLP-1) | 966 with MASH, F1B–F3; 52 weeks | Not a main result | 25.9%, 29.9% vs 9.7% | 24.2%, 25.9% vs 14.2% |

Sources by row: ESSENCE[3](https://pepvault.app/guides/glp-1-and-fatty-liver#source-3), SYNERGY-NASH[4](https://pepvault.app/guides/glp-1-and-fatty-liver#source-4), SURPASS-3 MRI[13](https://pepvault.app/guides/glp-1-and-fatty-liver#source-13) (an open-label comparison with insulin degludec, not placebo), survodutide phase 2[7](https://pepvault.app/guides/glp-1-and-fatty-liver#source-7), SYNCHRONIZE-MASLD[6](https://pepvault.app/guides/glp-1-and-fatty-liver#source-6) (efficacy estimand), retatrutide[5](https://pepvault.app/guides/glp-1-and-fatty-liver#source-5) (main result at 24 weeks), efinopegdutide[8](https://pepvault.app/guides/glp-1-and-fatty-liver#source-8), MAESTRO-NASH[9](https://pepvault.app/guides/glp-1-and-fatty-liver#source-9). The trials' doses are reported as the trials gave them, not as a dose for anyone.

Two numbers stand out. Retatrutide, which acts on three hormone receptors, took liver fat into the normal range, under 5%, in 79% of people on 8 mg and 86% on 12 mg at 24 weeks, against none on placebo[5](https://pepvault.app/guides/glp-1-and-fatty-liver#source-5). And semaglutide is the only GLP-1 so far with a phase 3 biopsy result, the kind regulators approve on[3](https://pepvault.app/guides/glp-1-and-fatty-liver#source-3). An older, smaller trial of daily liraglutide (Victoza's molecule) cleared MASH in 9 of 23 people against 2 of 22 on placebo over 48 weeks[16](https://pepvault.app/guides/glp-1-and-fatty-liver#source-16). Trial pages such as pepvault.app/research/survodutide-synchronize-masld-2026 give each study in full.

## With this guide

### Semaglutide

- [Semaglutide: the full reference](https://pepvault.app/peptides/semaglutide)
- [Semaglutide dose guide](https://pepvault.app/lab/dosage/semaglutide)

### Tirzepatide

- [Tirzepatide: the full reference](https://pepvault.app/peptides/tirzepatide)
- [Tirzepatide dose guide](https://pepvault.app/lab/dosage/tirzepatide)

### Mixing charts

- [Semaglutide 2 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-2mg)
- [Semaglutide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-5mg)
- [Semaglutide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-10mg)
- [Tirzepatide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-5mg)
- [Tirzepatide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-10mg)
- [Tirzepatide 15 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-15mg)
- [Tirzepatide 30 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-30mg)
- [Tirzepatide 60 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-60mg)

### Studies

- [Semaglutide: 11.85% more weight loss than placebo without diabetes](https://pepvault.app/research/semaglutide-tan-2022)
- [CagriSema: 18.4% weight loss vs 11.9% on semaglutide in REDEFINE 5](https://pepvault.app/research/cagrisema-redefine-5-2026)
- [CagriSema: HbA1c down 2.33% at 40 weeks in REIMAGINE 3](https://pepvault.app/research/cagrisema-reimagine-3-2026)
- [All 31 studies](https://pepvault.app/research#semaglutide)
- [Tirzepatide plus apitegromab: 1.9 kg less lean mass loss in EMBRAZE](https://pepvault.app/research/tirzepatide-embraze-2026)
- [Tirzepatide SURMOUNT-MAINTAIN: 21.9% weight loss at 112 weeks](https://pepvault.app/research/tirzepatide-surmount-maintain-2026)
- [Dulaglutide: switching to tirzepatide beat dose escalation on HbA1c](https://pepvault.app/research/dulaglutide-surpass-switch-2025)
- [All 19 studies](https://pepvault.app/research#tirzepatide)

### Compared with

- [Semaglutide vs Tirzepatide](https://pepvault.app/peptides/compare/semaglutide-vs-tirzepatide)
- [Retatrutide vs Semaglutide](https://pepvault.app/peptides/compare/retatrutide-vs-semaglutide)
- [Orforglipron vs Semaglutide](https://pepvault.app/peptides/compare/orforglipron-vs-semaglutide)
- [Cagrilintide vs Semaglutide](https://pepvault.app/peptides/compare/cagrilintide-vs-semaglutide)
- [Liraglutide vs Semaglutide](https://pepvault.app/peptides/compare/liraglutide-vs-semaglutide)
- [Semaglutide vs Dulaglutide](https://pepvault.app/peptides/compare/semaglutide-vs-dulaglutide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### The GLP-1 path

- [Retatrutide week by week](https://pepvault.app/guides/retatrutide-week-by-week)
- [Retatrutide dosage: the trial step-ups](https://pepvault.app/guides/retatrutide-dosage-in-trials)
- [Tirzepatide week by week](https://pepvault.app/guides/tirzepatide-week-by-week)
- [Semaglutide week by week](https://pepvault.app/guides/semaglutide-week-by-week)
- [Tirzepatide dosage: every step from 2.5 to 15 mg (Mounjaro and Zepbound)](https://pepvault.app/guides/tirzepatide-dosage)
- [Wegovy and Ozempic dosage: both labels' steps in one table, and why the two differ](https://pepvault.app/guides/wegovy-and-ozempic-dosage)
- [How to use the Zepbound KwikPen](https://pepvault.app/guides/how-to-use-the-zepbound-kwikpen)
- [How to use the Ozempic and Wegovy pens: needles, the dose counter and clicks](https://pepvault.app/guides/how-to-use-ozempic-and-wegovy-pens)
- [What time of day to take your GLP-1 shot or pill, and can you change the day?](https://pepvault.app/guides/when-to-take-your-glp-1)
- [Switching GLP-1s: Ozempic to Zepbound, shot to pill, and what the trials tested](https://pepvault.app/guides/switching-between-glp-1s)
- [Ozempic vs Wegovy vs Mounjaro vs Zepbound: the four labels in one table](https://pepvault.app/guides/ozempic-wegovy-mounjaro-zepbound)
- [Is Ozempic insulin? GLP-1, GIP and insulin explained](https://pepvault.app/guides/is-ozempic-insulin)
- [The Wegovy pill: what it is, how its label differs from the shot, and the trial numbers](https://pepvault.app/guides/the-wegovy-pill)
- [Ozempic and Wegovy side effects: what the trials counted and when they showed up](https://pepvault.app/guides/ozempic-and-wegovy-side-effects)
- [Semaglutide vs tirzepatide side effects: what the head-to-head trials found](https://pepvault.app/guides/sema-vs-tirzepatide-side-effects)
- [Microdosing a GLP-1: what it means and what has been tested](https://pepvault.app/guides/microdosing-a-glp-1)
- [GLP-1s and sleep apnea: Zepbound's OSA approval](https://pepvault.app/guides/glp-1-and-sleep-apnea)
- [Retatrutide first dose: the first four weeks in the trials](https://pepvault.app/guides/retatrutide-first-dose)
- [Retatrutide side effects: what the trials counted](https://pepvault.app/guides/retatrutide-side-effects)
- [Retatrutide not working? Stalls, slow responders and the plateau](https://pepvault.app/guides/retatrutide-not-working)
- [Switching from tirzepatide to retatrutide: what is known](https://pepvault.app/guides/tirzepatide-to-retatrutide)
- [Is retatrutide safe? What the trials reported](https://pepvault.app/guides/is-retatrutide-safe)
- [When will retatrutide be approved?](https://pepvault.app/guides/when-will-retatrutide-be-approved)
- [TRIUMPH-5 results: retatrutide vs tirzepatide head to head](https://pepvault.app/guides/triumph-5-results)
- [CagriSema FDA approval: when it's due, the dose filed, and what the trials showed](https://pepvault.app/guides/cagrisema-fda-decision)
- [MariTide phase 3 results (MARITIME-1): what to expect](https://pepvault.app/guides/maritime-1-results)
- [Aleniglipron: the GLP-1 pill, and the trial switching people from shots to it](https://pepvault.app/guides/aleniglipron-switch-trial)
- [Mounjaro and Zepbound side effects by dose: the rates at each step](https://pepvault.app/guides/mounjaro-zepbound-side-effects)
- [Hair loss on a GLP-1: how common it is per drug, and why](https://pepvault.app/guides/hair-loss-on-a-glp-1)
- ["Ozempic face": what it is, and where the weight comes from](https://pepvault.app/guides/ozempic-face)
- [Foundayo (orforglipron) vs the shots: the trial numbers side by side](https://pepvault.app/guides/foundayo-vs-the-shots)
- [Is compounded semaglutide or tirzepatide the same as Ozempic or Zepbound?](https://pepvault.app/guides/compounded-glp-1-vs-brand)
- [Why compounded semaglutide and tirzepatide come with B12, glycine or B6, and what it changes](https://pepvault.app/guides/compounded-glp-1-with-b12)
- [Is there a generic Ozempic? Generic semaglutide and Sevmia](https://pepvault.app/guides/generic-semaglutide)
- [How much does a GLP-1 cost in 2026? Zepbound, Wegovy and Medicare prices](https://pepvault.app/guides/how-much-does-a-glp-1-cost)
- [What to eat on a GLP-1: what the trials and the guidelines say](https://pepvault.app/guides/what-to-eat-on-a-glp-1)
- [How much protein per day? The numbers by weight and goal](https://pepvault.app/guides/how-much-protein-per-day)
- [Muscle on a GLP-1: how much of the weight lost is lean mass?](https://pepvault.app/guides/muscle-on-a-glp-1)
- [Intermittent fasting on a GLP-1: what the trials and labels say](https://pepvault.app/guides/intermittent-fasting-on-a-glp-1)
- [Coffee on a GLP-1: can you drink it, and why it can taste different](https://pepvault.app/guides/coffee-on-a-glp-1)
- [Food noise on a GLP-1: what it is and what happens after stopping](https://pepvault.app/guides/food-noise-on-a-glp-1)
- [GLP-1s and menopause: what the trials say about women in midlife](https://pepvault.app/guides/glp-1s-and-menopause)
- [Stopping a GLP-1: what happens to your weight](https://pepvault.app/guides/stopping-a-glp-1)
- [How to keep the weight off after a GLP-1: what each trial tested](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1)
- [Berberine vs metformin vs a GLP-1: what each does to weight and glucose](https://pepvault.app/guides/berberine-vs-metformin-vs-glp-1)
- [Natural GLP-1 alternatives: what the evidence shows for berberine, fiber and supplements](https://pepvault.app/guides/natural-glp-1-alternatives)
- [What is 5-Amino-1MQ? What's been measured](https://pepvault.app/guides/5-amino-1mq-explained)
- [Retatrutide from a lab vial: what independent testing found](https://pepvault.app/guides/retatrutide-lab-vial-tests)
- [Switching from Saxenda to Wegovy: how the change works](https://pepvault.app/guides/saxenda-to-wegovy)
- [Do you stop Ozempic, Wegovy, Mounjaro or Zepbound before surgery?](https://pepvault.app/guides/glp-1-before-surgery)
- [Diarrhea on a GLP-1: how common, and how long it lasts](https://pepvault.app/guides/diarrhea-on-a-glp-1)
- [Dizziness on a GLP-1: dehydration, blood pressure or blood sugar?](https://pepvault.app/guides/dizziness-on-a-glp-1)
- [Heartburn and acid reflux on a GLP-1: the rates, the timing and what helps](https://pepvault.app/guides/heartburn-on-a-glp-1)
- [Does Ozempic or Mounjaro make you tired? Fatigue in the trials](https://pepvault.app/guides/glp-1-fatigue)
- [Can a GLP-1 cause low blood sugar if you do not have diabetes?](https://pepvault.app/guides/glp-1-low-blood-sugar)
- [Is there a medicine for GLP-1 nausea? Tradipitant, so far](https://pepvault.app/guides/tradipitant-for-glp-1-nausea)
- [GLP-1s and mood: depression, anxiety and what the FDA review found](https://pepvault.app/guides/glp-1s-and-mood)
- [Can Ozempic cause vision loss? GLP-1s and NAION, by the numbers](https://pepvault.app/guides/glp-1-and-naion)
- [Are GLP-1s safe long term? What the longest trials show](https://pepvault.app/guides/are-glp-1s-safe-long-term)
- [GLP-1s and the kidneys: what FLOW showed, and the dehydration risk](https://pepvault.app/guides/glp-1s-and-the-kidneys)
- [Can you drink alcohol on Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/alcohol-on-a-glp-1)
- [Do GLP-1s reduce alcohol cravings? What the trials found](https://pepvault.app/guides/glp-1-and-alcohol-cravings)
- [GLP-1s after a gastric sleeve or bypass: regain, dosing and sleeve vs GLP-1](https://pepvault.app/guides/glp-1-after-bariatric-surgery)
- [Can you drink alcohol on retatrutide?](https://pepvault.app/guides/retatrutide-and-alcohol)
- [Ozempic, Wegovy, Mounjaro or Zepbound not working? Slow responders and plateaus in the trials](https://pepvault.app/guides/glp-1-not-working)
- [Intermittent fasting for weight and fat loss: what the trials measured](https://pepvault.app/guides/intermittent-fasting-weight-loss)
- [Can you take metformin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/metformin-with-a-glp-1)
- [GLP-1s and pregnancy: Ozempic, Wegovy, Mounjaro and Zepbound before and during](https://pepvault.app/guides/glp-1s-and-pregnancy)
- [Can you take Ozempic, Mounjaro or another GLP-1 while breastfeeding?](https://pepvault.app/guides/glp-1-while-breastfeeding)
- [Eloralintide, petrelintide and amycretin: the amylin drugs in trials](https://pepvault.app/guides/amylin-drugs-in-trials)
- [Olatorepatide (HS-20094): Regeneron's obesity drug, what is known so far](https://pepvault.app/guides/olatorepatide-explained)
- [Cagrilintide and CagriSema: what amylin adds to semaglutide](https://pepvault.app/guides/cagrilintide-and-cagrisema)
- [Berobenatide (PF-08653944, MET-097i): Pfizer's monthly GLP-1 shot, what is known so far](https://pepvault.app/guides/berobenatide-explained)
- [The GLP-1 pipeline: every drug in phase 2 and 3, and when its trials finish](https://pepvault.app/guides/glp-1-pipeline)
- [Is there a monthly GLP-1 shot? MariTide and berobenatide](https://pepvault.app/guides/monthly-glp-1-shots)
- [Cagrilintide alone: RENEW 1 phase 3 results and what to expect](https://pepvault.app/guides/renew-1-cagrilintide-results)
- [Wegovy HD: is 7.2 mg worth it, and what changes from 2.4 mg](https://pepvault.app/guides/wegovy-hd-7-2-mg)
- [Zenagamtide (amycretin): Novo's GLP-1 and amylin shot and pill, what the trials show](https://pepvault.app/guides/zenagamtide-amycretin)
- [Wegovy and Ozempic price, Medicare and WADA: what changes on January 1, 2027](https://pepvault.app/guides/glp-1-changes-january-2027)
- [Can you take sermorelin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/sermorelin-with-a-glp-1)
- [Retatrutide in women: what the studies included](https://pepvault.app/guides/retatrutide-in-women)
- [Peptides for women: what the trials in women show, and after 40](https://pepvault.app/guides/peptides-for-women)
- [Low-dose naltrexone (LDN) for weight loss: what the trials measured](https://pepvault.app/guides/ldn-for-weight-loss)
- [GLP-1s and PCOS: what the trials show, and how they compare with metformin](https://pepvault.app/guides/glp-1-and-pcos)
- [GLP-1s and sleep: insomnia, vivid dreams and the sleep apnea approval](https://pepvault.app/guides/glp-1s-and-sleep)

### Terms on this page

- [Peptide](https://pepvault.app/glossary/peptide)
- [GLP-1](https://pepvault.app/glossary/glp-1)
- [GIP](https://pepvault.app/glossary/gip)
- [Glucagon](https://pepvault.app/glossary/glucagon)
- [Placebo](https://pepvault.app/glossary/placebo)
- [Accelerated approval](https://pepvault.app/glossary/accelerated-approval)
- [Indication](https://pepvault.app/glossary/indication)
- [Open-label](https://pepvault.app/glossary/open-label)

## Why does liver fat fall so far on these drugs?

Mostly through weight. The liver stores the fat the body cannot use elsewhere, and losing body weight drains it. In a 52-week study of 293 people with biopsy-proven NASH who changed only diet and exercise, everyone who lost 10% or more of their weight saw their liver score improve, 90% saw NASH resolve and 45% saw scarring go back[14](https://pepvault.app/guides/glp-1-and-fatty-liver#source-14). GLP-1 drugs reach that weight loss more often: people in ESSENCE lost 10.5% of their weight against 2.0% on placebo[3](https://pepvault.app/guides/glp-1-and-fatty-liver#source-3). Wegovy's label says the mechanism in MASH is not fully understood and may run through weight loss and other pathways[1](https://pepvault.app/guides/glp-1-and-fatty-liver#source-1).

The newer drugs add a second lever. Glucagon, the hormone that tells the liver to release stored energy, acts on the liver directly. Survodutide and efinopegdutide act on both the GLP-1 and glucagon receptors, and retatrutide on GIP as well; these are called dual and triple agonists. The retatrutide authors write, drawing on animal studies, that glucagon may lower liver fat by making the liver burn more fat and build less; in their trial a blood marker of fat burning rose two- to threefold on 4 mg and above. They also cite an earlier trial in which efinopegdutide cut liver fat more than semaglutide at the same weight loss, a sign of a drop beyond what weight loss alone would give[5](https://pepvault.app/guides/glp-1-and-fatty-liver#source-5). No head-to-head trial has yet tested a dual agonist against semaglutide for MASH; the efinopegdutide trial gave open-label semaglutide 2.4 mg to one arm as a reference, and 53% of that group cleared MASH[8](https://pepvault.app/guides/glp-1-and-fatty-liver#source-8).

## Is less liver fat the same as a healthier liver?

It is an early sign, not the finish line. Fat on an MRI can fall within months (most of retatrutide's drop came in the first 24 weeks[5](https://pepvault.app/guides/glp-1-and-fatty-liver#source-5)), while scarring is what decides whether a liver goes on to cirrhosis. That is why the approvals rest on biopsies, and why both Wegovy and Rezdiffra carry a condition: the long trials still have to show fewer cases of cirrhosis, liver failure and death[2](https://pepvault.app/guides/glp-1-and-fatty-liver#source-2) [11](https://pepvault.app/guides/glp-1-and-fatty-liver#source-11). As of November 2026, no drug for MASH has published that outcome.

The outcome trials under way, as of November 2026, include Lilly's SYNERGY-Outcomes, which tests tirzepatide and retatrutide against placebo in about 4,500 people for cirrhosis, liver complications and deaths (NCT07165028), and Boehringer Ingelheim's LIVERAGE trials of survodutide in fibrosis and in cirrhosis (NCT06632444, NCT06632457), all recruiting.

<!--promo-->

PepVault logs your weekly shot and keeps your weigh-ins on one chart, and its Bloodwork page stores liver results such as ALT, AST and GGT by date, so the numbers your doctor follows sit in one place. [Track your weight in PepVault](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-glp-1-and-fatty-liver-inline&mt=8)

<!--/promo-->

## What about cirrhosis?

Here the GLP-1 data are thin. In a phase 2 trial of 71 people with MASH and compensated cirrhosis (scarred, but the liver still working), semaglutide 2.4 mg did no better than placebo over 48 weeks: scarring improved in 11% against 29%, a gap that was not statistically significant, and MASH resolution did not differ either[15](https://pepvault.app/guides/glp-1-and-fatty-liver#source-15). Both approved MASH drugs are labeled for livers without cirrhosis, and Rezdiffra's label says to avoid it in decompensated cirrhosis, the stage where the liver begins to fail[1](https://pepvault.app/guides/glp-1-and-fatty-liver#source-1) [11](https://pepvault.app/guides/glp-1-and-fatty-liver#source-11). Only 7% of people in Wegovy's MASH trial had a BMI under 25, and its label says information on that group is limited[1](https://pepvault.app/guides/glp-1-and-fatty-liver#source-1).

**When to get help** Yellowing of the skin or the whites of the eyes, or a belly that swells with fluid, can be a sign of advanced liver disease and is a reason to see your doctor soon[18](https://pepvault.app/guides/glp-1-and-fatty-liver#source-18).

## How does Wegovy compare with Rezdiffra for MASH?

They work in different ways. Rezdiffra is a daily tablet that switches on a thyroid hormone receptor found in the liver (THR-beta), dosed by body weight on its label, 80 mg under 100 kg and 100 mg at 100 kg or more[11](https://pepvault.app/guides/glp-1-and-fatty-liver#source-11). Beyond its liver results in the table above, it lowered LDL cholesterol by 13.6% and 16.3% at 24 weeks in its phase 3 trial[9](https://pepvault.app/guides/glp-1-and-fatty-liver#source-9). Wegovy is a weekly shot whose effect on MASH runs partly through weight loss, with a 63% against 34% MASH result in its own trial[1](https://pepvault.app/guides/glp-1-and-fatty-liver#source-1). The two trials enrolled different people, so their numbers are not a head-to-head comparison.

Whether a liver needs treatment, and which drug fits, is your doctor's decision, usually a liver specialist's, made from your blood tests, scans or a biopsy, your weight, and your other conditions. What this page shows is what each drug was measured to do.

Side effects in the MASH trials looked like each drug's other uses. Wegovy's label says the most common reactions in its MASH trial matched its weight-loss trials, led by nausea, diarrhea and other stomach effects[1](https://pepvault.app/guides/glp-1-and-fatty-liver#source-1); for tirzepatide and survodutide too, the most common were gut-related, mostly mild to moderate[4](https://pepvault.app/guides/glp-1-and-fatty-liver#source-4) [7](https://pepvault.app/guides/glp-1-and-fatty-liver#source-7). The label also lists fractures in the MASH trial in 4.4% of people on Wegovy against 3.3% on placebo[1](https://pepvault.app/guides/glp-1-and-fatty-liver#source-1). The full list is at pepvault.app/peptides/semaglutide/side-effects.

**Commonly reported:** people on a GLP-1 for weight often say a routine blood test showed their liver enzymes, usually ALT, back in the normal range, or that a follow-up scan showed less fat. These are users' own accounts, not trial measures.

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-next&mt=8)

<!--/promo-->

## Sources

1. Wegovy (semaglutide) injection and tablets, prescribing information (§1, §6.1, §12.1, §14.4 and Table 21). Novo Nordisk. DailyMed, published June 30, 2026. [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b)
2. US FDA. Approval letter, NDA 215256/S-024 (Wegovy), accelerated approval for noncirrhotic MASH with moderate to advanced liver fibrosis. August 15, 2025. [accessdata.fda.gov](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/215256Orig1s024ltr.pdf)
3. Sanyal AJ et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis (ESSENCE). N Engl J Med. 2025;392(21):2089-2099. [PubMed 40305708](https://pubmed.ncbi.nlm.nih.gov/40305708/)
4. Loomba R et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis (SYNERGY-NASH). N Engl J Med. 2024;391(4):299-310. [PubMed 38856224](https://pubmed.ncbi.nlm.nih.gov/38856224/)
5. Sanyal AJ et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(7):2037-2048. [PubMed 38858523](https://pubmed.ncbi.nlm.nih.gov/38858523/)
6. Kaplan LM et al. Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial. Nat Med. 2026;32(8):2948-2958. [PubMed 42252333](https://pubmed.ncbi.nlm.nih.gov/42252333/)
7. Sanyal AJ et al. A phase 2 randomized trial of survodutide in MASH and fibrosis. N Engl J Med. 2024;391(4):311-319. [PubMed 38847460](https://pubmed.ncbi.nlm.nih.gov/38847460/)
8. Lawitz E et al. Efficacy and safety of efinopegdutide in adults with metabolic dysfunction-associated steatohepatitis and stage 2-3 fibrosis: a phase 2b, randomised, placebo-controlled study. Lancet. 2026 (online November 9). [PubMed 43003105](https://pubmed.ncbi.nlm.nih.gov/43003105/)
9. Harrison SA et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis (MAESTRO-NASH). N Engl J Med. 2024;390(6):497-509. [PubMed 38324483](https://pubmed.ncbi.nlm.nih.gov/38324483/)
10. US FDA. FDA approves first treatment for patients with liver scarring due to fatty liver disease. Press announcement, March 14, 2024. [fda.gov](https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease)
11. Rezdiffra (resmetirom) tablets, prescribing information. Madrigal Pharmaceuticals. DailyMed, published August 5, 2026. [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e67ea09f-a840-439c-86c8-f98585f978b2)
12. Rinella ME et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966-1986. [PubMed 37363821](https://pubmed.ncbi.nlm.nih.gov/37363821/)
13. Gastaldelli A et al. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI). Lancet Diabetes Endocrinol. 2022;10(6):393-406. [PubMed 35468325](https://pubmed.ncbi.nlm.nih.gov/35468325/)
14. Vilar-Gomez E et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149(2):367-378. [PubMed 25865049](https://pubmed.ncbi.nlm.nih.gov/25865049/)
15. Loomba R et al. Semaglutide 2.4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8(6):511-522. [PubMed 36934740](https://pubmed.ncbi.nlm.nih.gov/36934740/)
16. Armstrong MJ et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387(10019):679-690. [PubMed 26608256](https://pubmed.ncbi.nlm.nih.gov/26608256/)
17. Medicines and Healthcare products Regulatory Agency (UK). Semaglutide (Wegovy) approved to treat form of liver disease. July 3, 2026. [gov.uk](https://www.gov.uk/government/news/semaglutide-wegovy-approved-to-treat-form-of-liver-disease)
18. National Institute of Diabetes and Digestive and Kidney Diseases (NIH). Symptoms and causes of cirrhosis. Reviewed June 2023. [niddk.nih.gov](https://www.niddk.nih.gov/health-information/liver-disease/cirrhosis/symptoms-causes)
19. Ozempic (semaglutide) injection, prescribing information. Novo Nordisk. DailyMed, effective June 2026. [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79)
20. Zepbound (tirzepatide) injection, prescribing information. Eli Lilly and Company. DailyMed, revised August 2026. [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b)
21. Mounjaro (tirzepatide) injection, prescribing information. Eli Lilly and Company. DailyMed, revised August 2026. [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0)

<!--promo-->

Newsletter · Weekly

## The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

<!--/promo-->

## Next guide · GLP-1

Guide · GLP-1

### [GLP-1s after a gastric sleeve or bypass: regain, dosing and sleeve vs GLP-1](https://pepvault.app/guides/glp-1-after-bariatric-surgery)

Do GLP-1s work after a gastric sleeve or bypass? The trials on regain, the labels' doses side by side, side effects after surgery, and sleeve vs GLP-1 numbers.

Read the next guide

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-end&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

## In the library

- [Semaglutide Studied range: 0.25–2.4 mg](https://pepvault.app/peptides/semaglutide)
- [Tirzepatide Studied range: 2.5–15 mg](https://pepvault.app/peptides/tirzepatide)
- [Retatrutide Studied range: 1–12 mg](https://pepvault.app/peptides/retatrutide)
- [Survodutide Studied range: 0.3–6 mg](https://pepvault.app/peptides/survodutide)
- [Efinopegdutide Studied range: 4–10 mg](https://pepvault.app/peptides/efinopegdutide)
- [Liraglutide Studied range: 0.6–3 mg](https://pepvault.app/peptides/liraglutide)

## Related guides

- Guide · GLP-1s

  ### [Ozempic vs Wegovy vs Mounjaro vs Zepbound: the four labels in one table](https://pepvault.app/guides/ozempic-wegovy-mounjaro-zepbound)

  Ozempic, Wegovy, Mounjaro and Zepbound side by side: ingredient, approved use, dose steps, top dose, missed-dose rule and trial weight loss, from each FDA label

  Read the guide
- Guide · GLP-1s

  ### [Semaglutide week by week](https://pepvault.app/guides/semaglutide-week-by-week)

  What to expect on semaglutide week by week: the Wegovy label's dose steps, what the STEP trials saw at each stage, appetite, side effects and the plateau.

  Read the guide
- Guide · GLP-1s

  ### [Stopping a GLP-1: what happens to your weight](https://pepvault.app/guides/stopping-a-glp-1)

  What happened to weight when semaglutide and tirzepatide were stopped in STEP 1, STEP 4 and SURMOUNT-4: how much came back, how fast, and what the labels say.

  Read the guide
- Guide · GLP-1s

  ### [Retatrutide week by week](https://pepvault.app/guides/retatrutide-week-by-week)

  What to expect on retatrutide week by week: the trial dose steps, when appetite drops, weight loss at weeks 24, 48 and 80, and how side effects settle.

  Read the guide

## Guides

- [All guides](https://pepvault.app/guides)
- [How we research](https://pepvault.app/guides/how-we-research)

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-rail&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## With this guide

### Semaglutide

- [Semaglutide: the full reference](https://pepvault.app/peptides/semaglutide)
- [Semaglutide dose guide](https://pepvault.app/lab/dosage/semaglutide)

### Tirzepatide

- [Tirzepatide: the full reference](https://pepvault.app/peptides/tirzepatide)
- [Tirzepatide dose guide](https://pepvault.app/lab/dosage/tirzepatide)

### Mixing charts

- [Semaglutide 2 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-2mg)
- [Semaglutide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-5mg)
- [Semaglutide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-10mg)
- [Tirzepatide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-5mg)
- [Tirzepatide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-10mg)
- [Tirzepatide 15 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-15mg)
- [Tirzepatide 30 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-30mg)
- [Tirzepatide 60 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-60mg)

### Studies

- [Semaglutide: 11.85% more weight loss than placebo without diabetes](https://pepvault.app/research/semaglutide-tan-2022)
- [CagriSema: 18.4% weight loss vs 11.9% on semaglutide in REDEFINE 5](https://pepvault.app/research/cagrisema-redefine-5-2026)
- [CagriSema: HbA1c down 2.33% at 40 weeks in REIMAGINE 3](https://pepvault.app/research/cagrisema-reimagine-3-2026)
- [All 31 studies](https://pepvault.app/research#semaglutide)
- [Tirzepatide plus apitegromab: 1.9 kg less lean mass loss in EMBRAZE](https://pepvault.app/research/tirzepatide-embraze-2026)
- [Tirzepatide SURMOUNT-MAINTAIN: 21.9% weight loss at 112 weeks](https://pepvault.app/research/tirzepatide-surmount-maintain-2026)
- [Dulaglutide: switching to tirzepatide beat dose escalation on HbA1c](https://pepvault.app/research/dulaglutide-surpass-switch-2025)
- [All 19 studies](https://pepvault.app/research#tirzepatide)

### Compared with

- [Semaglutide vs Tirzepatide](https://pepvault.app/peptides/compare/semaglutide-vs-tirzepatide)
- [Retatrutide vs Semaglutide](https://pepvault.app/peptides/compare/retatrutide-vs-semaglutide)
- [Orforglipron vs Semaglutide](https://pepvault.app/peptides/compare/orforglipron-vs-semaglutide)
- [Cagrilintide vs Semaglutide](https://pepvault.app/peptides/compare/cagrilintide-vs-semaglutide)
- [Liraglutide vs Semaglutide](https://pepvault.app/peptides/compare/liraglutide-vs-semaglutide)
- [Semaglutide vs Dulaglutide](https://pepvault.app/peptides/compare/semaglutide-vs-dulaglutide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### The GLP-1 path

- [Retatrutide week by week](https://pepvault.app/guides/retatrutide-week-by-week)
- [Retatrutide dosage: the trial step-ups](https://pepvault.app/guides/retatrutide-dosage-in-trials)
- [Tirzepatide week by week](https://pepvault.app/guides/tirzepatide-week-by-week)
- [Semaglutide week by week](https://pepvault.app/guides/semaglutide-week-by-week)
- [Tirzepatide dosage: every step from 2.5 to 15 mg (Mounjaro and Zepbound)](https://pepvault.app/guides/tirzepatide-dosage)
- [Wegovy and Ozempic dosage: both labels' steps in one table, and why the two differ](https://pepvault.app/guides/wegovy-and-ozempic-dosage)
- [How to use the Zepbound KwikPen](https://pepvault.app/guides/how-to-use-the-zepbound-kwikpen)
- [How to use the Ozempic and Wegovy pens: needles, the dose counter and clicks](https://pepvault.app/guides/how-to-use-ozempic-and-wegovy-pens)
- [What time of day to take your GLP-1 shot or pill, and can you change the day?](https://pepvault.app/guides/when-to-take-your-glp-1)
- [Switching GLP-1s: Ozempic to Zepbound, shot to pill, and what the trials tested](https://pepvault.app/guides/switching-between-glp-1s)
- [Ozempic vs Wegovy vs Mounjaro vs Zepbound: the four labels in one table](https://pepvault.app/guides/ozempic-wegovy-mounjaro-zepbound)
- [Is Ozempic insulin? GLP-1, GIP and insulin explained](https://pepvault.app/guides/is-ozempic-insulin)
- [The Wegovy pill: what it is, how its label differs from the shot, and the trial numbers](https://pepvault.app/guides/the-wegovy-pill)
- [Ozempic and Wegovy side effects: what the trials counted and when they showed up](https://pepvault.app/guides/ozempic-and-wegovy-side-effects)
- [Semaglutide vs tirzepatide side effects: what the head-to-head trials found](https://pepvault.app/guides/sema-vs-tirzepatide-side-effects)
- [Microdosing a GLP-1: what it means and what has been tested](https://pepvault.app/guides/microdosing-a-glp-1)
- [GLP-1s and sleep apnea: Zepbound's OSA approval](https://pepvault.app/guides/glp-1-and-sleep-apnea)
- [Retatrutide first dose: the first four weeks in the trials](https://pepvault.app/guides/retatrutide-first-dose)
- [Retatrutide side effects: what the trials counted](https://pepvault.app/guides/retatrutide-side-effects)
- [Retatrutide not working? Stalls, slow responders and the plateau](https://pepvault.app/guides/retatrutide-not-working)
- [Switching from tirzepatide to retatrutide: what is known](https://pepvault.app/guides/tirzepatide-to-retatrutide)
- [Is retatrutide safe? What the trials reported](https://pepvault.app/guides/is-retatrutide-safe)
- [When will retatrutide be approved?](https://pepvault.app/guides/when-will-retatrutide-be-approved)
- [TRIUMPH-5 results: retatrutide vs tirzepatide head to head](https://pepvault.app/guides/triumph-5-results)
- [CagriSema FDA approval: when it's due, the dose filed, and what the trials showed](https://pepvault.app/guides/cagrisema-fda-decision)
- [MariTide phase 3 results (MARITIME-1): what to expect](https://pepvault.app/guides/maritime-1-results)
- [Aleniglipron: the GLP-1 pill, and the trial switching people from shots to it](https://pepvault.app/guides/aleniglipron-switch-trial)
- [Mounjaro and Zepbound side effects by dose: the rates at each step](https://pepvault.app/guides/mounjaro-zepbound-side-effects)
- [Hair loss on a GLP-1: how common it is per drug, and why](https://pepvault.app/guides/hair-loss-on-a-glp-1)
- ["Ozempic face": what it is, and where the weight comes from](https://pepvault.app/guides/ozempic-face)
- [Foundayo (orforglipron) vs the shots: the trial numbers side by side](https://pepvault.app/guides/foundayo-vs-the-shots)
- [Is compounded semaglutide or tirzepatide the same as Ozempic or Zepbound?](https://pepvault.app/guides/compounded-glp-1-vs-brand)
- [Why compounded semaglutide and tirzepatide come with B12, glycine or B6, and what it changes](https://pepvault.app/guides/compounded-glp-1-with-b12)
- [Is there a generic Ozempic? Generic semaglutide and Sevmia](https://pepvault.app/guides/generic-semaglutide)
- [How much does a GLP-1 cost in 2026? Zepbound, Wegovy and Medicare prices](https://pepvault.app/guides/how-much-does-a-glp-1-cost)
- [What to eat on a GLP-1: what the trials and the guidelines say](https://pepvault.app/guides/what-to-eat-on-a-glp-1)
- [How much protein per day? The numbers by weight and goal](https://pepvault.app/guides/how-much-protein-per-day)
- [Muscle on a GLP-1: how much of the weight lost is lean mass?](https://pepvault.app/guides/muscle-on-a-glp-1)
- [Intermittent fasting on a GLP-1: what the trials and labels say](https://pepvault.app/guides/intermittent-fasting-on-a-glp-1)
- [Coffee on a GLP-1: can you drink it, and why it can taste different](https://pepvault.app/guides/coffee-on-a-glp-1)
- [Food noise on a GLP-1: what it is and what happens after stopping](https://pepvault.app/guides/food-noise-on-a-glp-1)
- [GLP-1s and menopause: what the trials say about women in midlife](https://pepvault.app/guides/glp-1s-and-menopause)
- [Stopping a GLP-1: what happens to your weight](https://pepvault.app/guides/stopping-a-glp-1)
- [How to keep the weight off after a GLP-1: what each trial tested](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1)
- [Berberine vs metformin vs a GLP-1: what each does to weight and glucose](https://pepvault.app/guides/berberine-vs-metformin-vs-glp-1)
- [Natural GLP-1 alternatives: what the evidence shows for berberine, fiber and supplements](https://pepvault.app/guides/natural-glp-1-alternatives)
- [What is 5-Amino-1MQ? What's been measured](https://pepvault.app/guides/5-amino-1mq-explained)
- [Retatrutide from a lab vial: what independent testing found](https://pepvault.app/guides/retatrutide-lab-vial-tests)
- [Switching from Saxenda to Wegovy: how the change works](https://pepvault.app/guides/saxenda-to-wegovy)
- [Do you stop Ozempic, Wegovy, Mounjaro or Zepbound before surgery?](https://pepvault.app/guides/glp-1-before-surgery)
- [Diarrhea on a GLP-1: how common, and how long it lasts](https://pepvault.app/guides/diarrhea-on-a-glp-1)
- [Dizziness on a GLP-1: dehydration, blood pressure or blood sugar?](https://pepvault.app/guides/dizziness-on-a-glp-1)
- [Heartburn and acid reflux on a GLP-1: the rates, the timing and what helps](https://pepvault.app/guides/heartburn-on-a-glp-1)
- [Does Ozempic or Mounjaro make you tired? Fatigue in the trials](https://pepvault.app/guides/glp-1-fatigue)
- [Can a GLP-1 cause low blood sugar if you do not have diabetes?](https://pepvault.app/guides/glp-1-low-blood-sugar)
- [Is there a medicine for GLP-1 nausea? Tradipitant, so far](https://pepvault.app/guides/tradipitant-for-glp-1-nausea)
- [GLP-1s and mood: depression, anxiety and what the FDA review found](https://pepvault.app/guides/glp-1s-and-mood)
- [Can Ozempic cause vision loss? GLP-1s and NAION, by the numbers](https://pepvault.app/guides/glp-1-and-naion)
- [Are GLP-1s safe long term? What the longest trials show](https://pepvault.app/guides/are-glp-1s-safe-long-term)
- [GLP-1s and the kidneys: what FLOW showed, and the dehydration risk](https://pepvault.app/guides/glp-1s-and-the-kidneys)
- [Can you drink alcohol on Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/alcohol-on-a-glp-1)
- [Do GLP-1s reduce alcohol cravings? What the trials found](https://pepvault.app/guides/glp-1-and-alcohol-cravings)
- [GLP-1s after a gastric sleeve or bypass: regain, dosing and sleeve vs GLP-1](https://pepvault.app/guides/glp-1-after-bariatric-surgery)
- [Can you drink alcohol on retatrutide?](https://pepvault.app/guides/retatrutide-and-alcohol)
- [Ozempic, Wegovy, Mounjaro or Zepbound not working? Slow responders and plateaus in the trials](https://pepvault.app/guides/glp-1-not-working)
- [Intermittent fasting for weight and fat loss: what the trials measured](https://pepvault.app/guides/intermittent-fasting-weight-loss)
- [Can you take metformin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/metformin-with-a-glp-1)
- [GLP-1s and pregnancy: Ozempic, Wegovy, Mounjaro and Zepbound before and during](https://pepvault.app/guides/glp-1s-and-pregnancy)
- [Can you take Ozempic, Mounjaro or another GLP-1 while breastfeeding?](https://pepvault.app/guides/glp-1-while-breastfeeding)
- [Eloralintide, petrelintide and amycretin: the amylin drugs in trials](https://pepvault.app/guides/amylin-drugs-in-trials)
- [Olatorepatide (HS-20094): Regeneron's obesity drug, what is known so far](https://pepvault.app/guides/olatorepatide-explained)
- [Cagrilintide and CagriSema: what amylin adds to semaglutide](https://pepvault.app/guides/cagrilintide-and-cagrisema)
- [Berobenatide (PF-08653944, MET-097i): Pfizer's monthly GLP-1 shot, what is known so far](https://pepvault.app/guides/berobenatide-explained)
- [The GLP-1 pipeline: every drug in phase 2 and 3, and when its trials finish](https://pepvault.app/guides/glp-1-pipeline)
- [Is there a monthly GLP-1 shot? MariTide and berobenatide](https://pepvault.app/guides/monthly-glp-1-shots)
- [Cagrilintide alone: RENEW 1 phase 3 results and what to expect](https://pepvault.app/guides/renew-1-cagrilintide-results)
- [Wegovy HD: is 7.2 mg worth it, and what changes from 2.4 mg](https://pepvault.app/guides/wegovy-hd-7-2-mg)
- [Zenagamtide (amycretin): Novo's GLP-1 and amylin shot and pill, what the trials show](https://pepvault.app/guides/zenagamtide-amycretin)
- [Wegovy and Ozempic price, Medicare and WADA: what changes on January 1, 2027](https://pepvault.app/guides/glp-1-changes-january-2027)
- [Can you take sermorelin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/sermorelin-with-a-glp-1)
- [Retatrutide in women: what the studies included](https://pepvault.app/guides/retatrutide-in-women)
- [Peptides for women: what the trials in women show, and after 40](https://pepvault.app/guides/peptides-for-women)
- [Low-dose naltrexone (LDN) for weight loss: what the trials measured](https://pepvault.app/guides/ldn-for-weight-loss)
- [GLP-1s and PCOS: what the trials show, and how they compare with metformin](https://pepvault.app/guides/glp-1-and-pcos)
- [GLP-1s and sleep: insomnia, vivid dreams and the sleep apnea approval](https://pepvault.app/guides/glp-1s-and-sleep)

### Terms on this page

- [Peptide](https://pepvault.app/glossary/peptide)
- [GLP-1](https://pepvault.app/glossary/glp-1)
- [GIP](https://pepvault.app/glossary/gip)
- [Glucagon](https://pepvault.app/glossary/glucagon)
- [Placebo](https://pepvault.app/glossary/placebo)
- [Accelerated approval](https://pepvault.app/glossary/accelerated-approval)
- [Indication](https://pepvault.app/glossary/indication)
- [Open-label](https://pepvault.app/glossary/open-label)

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-sticky&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it.

© 2026 PepVault. Our text, data and tools may not be copied, scraped or republished without [permission](https://pepvault.app/terms#content).
